• Establishment of an ex Vivo Tumor Collection of Triple-negative Breast Cancers in Order to Validate the Interest of Innovative Therapies and the Search for Predictive Biomarkers of Response to Treatment

  NCT05404321

  RecruitingObservationalUpdated Mar 19, 2026
• Development of Tumor Organoids From Undifferentiated Primary Carcinomas to Guide Therapeutic Decisions

  NCT06612827

  RecruitingObservationalUpdated Dec 24, 2025
• Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer

  NCT02572778

  RecruitingObservationalUpdated Dec 3, 2024
• SOTO: Treatment Sensitivity of Organoids to Predict Treatment Outcome

  NCT05400239

  Unknown statusObservationalUpdated Mar 21, 2024
• Using a 3D Culture Model for Circulating Tumor Cells Combined With Molecular Bioassays in Patients With HNSCC Cancer

  NCT06755762

  RecruitingObservationalUpdated Jan 1, 2025
• High Throughput Screening Device Based on 3D Nano-matrices and 3D Tumors With Functional Vascularization

  NCT04826913

  Unknown statusObservationalUpdated Apr 1, 2021

ClinicalTrials.gov ID

NCT04261192

Lead Sponsor

Centre Francois BaclesseOTHER

Overall Status

Recruiting

Study Type

Observational

Enrollment

120Estimated

Last Update Posted

May 12, 2026Actual

Start Date

Jul 3, 2020Actual

Primary Completion Date

Feb 2027Estimated

Completion Date

Feb 2032Estimated

Official Title

Establishment of Squamous Cell Organoids of the Head and Neck to Assess Their Response to Innovative Therapies

Brief Summary

The emergence of tumor organoid cultures in recent years has made it possible to widen the repertoire of available preclinical tumor models and to bridge the gap between cell lines and tumors of xenografted patients in mice (PDXs).These organoids have the advantages of being able to be amplified fairly quickly after resection of the tumor, of having unlimited proliferation potential, a high rate of establishment success, and the possibility of being transfected and cryopreserved. These characteristics therefore allow them to summarize the clinical spectra of cancers, but also to be models for studying tumor progression as has been done with organoids for colorectal cancer. They are also very close morphologically and genetically to the tumor from which they derive.Finally, clinical trials are underway to determine whether the organoids of mammary, pulmonary and colorectal cancers can predict the response to patients' treatments and guide the therapeutic decision.It would therefore be possible to test multiple treatments on different samples. This would allow screening of a panel of treatments on a given tumor type but also to test a treatment ex vivo before administering it to the patient in vivo. This prospect is very interesting in particular in the tumors of the VADS where more than two thirds of the operated patients will benefit from a complementary treatment by radiotherapy and / or chemotherapy whose consequences can be important. Despite this adjuvant management, up to 30% of patients will relapse, highlighting a variable tumor chemosensitivity. This screening could make it possible to refine the choice of treatments adapted to each patient and thus limit the undesirable effects.The feasibility of establishing head and neck squamous cell organoid lines seems encouraging, with organoids derived from squamous cell carcinoma of the oral cavity and oropharynx having been recently established.

• Head and Neck Cancer

• Constitution of tumor and blood samples

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Patient over 18 years of age;
• Patient with squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx, classified T3Nx or T4Nx or T2N +, not previously treated;
• Patient to be treated by surgery;
• Patient affiliated to a social security scheme;
• No opposition to participate in the study

Exclusion Criteria:

• Pregnant woman ;
• Persons deprived of their liberty or under guardianship (including curatorship);
• History of malignant pathology preceding inclusion (apart from basal cell carcinomas of the skin and carcinomas in situ of the cervix treated surgically) or concomitant at inclusion (synchronous tumor)

Observational Model

Cohort

Time Perspective

Prospective

Lead Sponsor

Centre Francois BaclesseOTHER

bastit-v@chu-caen.fr